Chemically controlled aggregation of pluripotent stem cells

Abstract Heterogeneity in pluripotent stem cell (PSC) aggregation leads to variability in mass transfer and signaling gradients between aggregates, which results in heterogeneous differentiation and therefore variability in product quality and yield. We have characterized a chemical‐based method to control aggregate size within a specific, tunable range with low heterogeneity, thereby reducing process variability in PSC expansion. This method enables controlled, scalable, stirred suspension‐based manufacturing of PSC cultures that are critical for the translation of regenerative medicine strategies to clinical products.

[1]  J. Crook,et al.  Attachment and growth of human embryonic stem cells on microcarriers. , 2008, Journal of biotechnology.

[2]  Peter W Zandstra,et al.  Quality cell therapy manufacturing by design , 2016, Nature Biotechnology.

[3]  P. Zandstra,et al.  Reproducible, Ultra High-Throughput Formation of Multicellular Organization from Single Cell Suspension-Derived Human Embryonic Stem Cell Aggregates , 2008, PloS one.

[4]  W. Renner,et al.  Cell–cell adhesion and aggregation: Influence on the growth behavior of CHO cells , 1993, Biotechnology and bioengineering.

[5]  J. Itskovitz‐Eldor,et al.  Dynamic suspension culture for scalable expansion of undifferentiated human pluripotent stem cells , 2011, Nature Protocols.

[6]  Todd C McDevitt,et al.  Aggregate formation and suspension culture of human pluripotent stem cells and differentiated progeny. , 2016, Methods.

[7]  M. J. Stanley,et al.  Heparan Sulfate-mediated Cell Aggregation , 1995, The Journal of Biological Chemistry.

[8]  Jin Hyoung Park,et al.  The molecular weight and concentration of dextran sulfate affect cell growth and antibody production in CHO cell cultures , 2016, Biotechnology progress.

[9]  H. A. Wood,et al.  Inducing single-cell suspension of BTI-TN5B1-4 insect cells: I. The use of sulfated polyanions to prevent cell aggregation and enhance recombinant protein production. , 1997, Biotechnology and bioengineering.

[10]  Robert Zweigerdt,et al.  Scalable expansion of human pluripotent stem cells in suspension culture , 2011, Nature Protocols.

[11]  D. Kehoe,et al.  Scalable stirred-suspension bioreactor culture of human pluripotent stem cells. , 2010, Tissue engineering. Part A.

[12]  S. Reuveny,et al.  Critical microcarrier properties affecting the expansion of undifferentiated human embryonic stem cells. , 2011, Stem cell research.

[13]  Rong Liu,et al.  Heparin Promotes Suspension Adaptation Process of CHO–TS28 Cells by Eliminating Cell Aggregation , 2011, Molecular biotechnology.

[14]  Peter W. Zandstra,et al.  Rational bioprocess design for human pluripotent stem cell expansion and endoderm differentiation based on cellular dynamics. , 2012, Biotechnology and bioengineering.

[15]  Kumaraswamy Nanthakumar,et al.  Geometric control of cardiomyogenic induction in human pluripotent stem cells. , 2011, Tissue engineering. Part A.

[16]  Nicholas R. Abu-Absi,et al.  Dextran sulfate inhibits staurosporine-induced apoptosis in Chinese hamster ovary (CHO) cells: Involvement of the mitochondrial pathway , 2011 .

[17]  M. Fussenegger,et al.  The Growth Factor Inhibitor Suramin Reduces Apoptosis and Cell Aggregation in Protein‐Free CHO Cell Batch Cultures , 2000, Biotechnology progress.

[18]  I. Amit,et al.  Derivation of novel human ground state naive pluripotent stem cells , 2013, Nature.

[19]  S. Reuveny,et al.  Long-term microcarrier suspension cultures of human embryonic stem cells. , 2009, Stem cell research.

[20]  Peter W. Zandstra,et al.  Derivation, expansion and differentiation of induced pluripotent stem cells in continuous suspension cultures , 2012, Nature Methods.